Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective
Objective This study aimed to estimate the cost-effectiveness of direct-acting antivirals (DAAs) among patients with non-genotype 1 for the eradication of hepatitis C virus (HCV) infection in China.Methods A decision-analytic Markov model was developed to estimate the lifetime costs, quality-adjuste...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | BMJ Global Health |
Online Access: | https://gh.bmj.com/content/5/11/e003194.full |